Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestogen (hormonal contraceptive) presented as an intrauterine system for intrauterine use. It provides long‑term reversible contraception by releasing levonorgestrel locally to prevent pregnancy in women of reproductive age and is approved in the European Union for up to three years of continuous use.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Jaydess, a levonorgestrel intrauterine system, is used within the contraceptive pathway to prevent unintended pregnancy.

- Contraception: provides up to three years of highly effective pregnancy prevention. - Hormonal birth control: delivers a steady low dose of levonorgestrel directly to the uterine lining. - Intrauterine device therapy: offers a reversible, non‑daily method for women seeking long‑term contraception.

Levonorgestrel released from the intrauterine system can be associated with a range of adverse reactions.

Common Side Effects: - Irregular bleeding or spotting, especially in the first months. - Amenorrhea (absence of menstrual bleeding) after continued use. - Pelvic or abdominal discomfort. - Breast tenderness or mild headache. - Acne or oily skin changes.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Expulsion of the device. - Pelvic inflammatory disease or infection. - Ectopic pregnancy if contraception fails.

Before insertion and during use, several precautions should be observed to ensure safety and effectiveness.

- Confirm non‑pregnancy: verify the patient is not pregnant prior to insertion. - Evaluate uterine anatomy: assess for fibroids, septa, or other abnormalities. - Treat active infections: resolve pelvic or cervical infections before device placement. - Counsel on bleeding changes: inform patients about possible irregular bleeding patterns. - Review contraindications: avoid use in women with known or suspected malignancy, liver disease, or unexplained vaginal bleeding. - Store at ambient temperature: keep the device in its original packaging, protected from moisture and direct sunlight.

Levonorgestrel IUS may interact with other medicines that affect hormone metabolism or uterine environment.

Major Interactions (Avoid): - Strong enzyme inducers such as rifampicin, carbamazepine, or phenytoin, which may reduce levonorgestrel efficacy. - Antiretroviral drugs like efavirenz that accelerate hormonal clearance. - St John’s wort, a herbal inducer of CYP enzymes, potentially decreasing contraceptive effect.

Moderate Interactions (Monitor Closely): - Certain antifungal agents (e.g., ketoconazole) that can alter hormone levels. - Antibiotics such as tetracycline that may affect gut flora and hormone reabsorption. - Anticonvulsants with moderate inducing activity (e.g., phenobarbital) requiring monitoring.